[Ip-health] Human Rights Council Social Forum 2015: Intervention of Knowledge Ecology International
thiru at keionline.org
Fri Feb 20 08:02:10 PST 2015
Human Rights Council Social Forum 2015: Intervention of Knowledge Ecology
Submitted by thiru <http://keionline.org/user/6> on 20. February 2015 -
20 February 2015
In accordance with Human Rights Council resolution A/HRC/RES/26/28
the Human Rights Council convened the 2015 Social Forum at the United
Nations Palais des Nations in Geneva from 18-20, February 2015 with a focus
on "access to medicines in the context of the right of everyone to the
enjoyment of the highest attainable standard of physical and mental health,
including best practices in this regard."
The program for the Social Forum 2015 can be found here
On Friday, 20 February 2015, in a roundtable on good practices in promoting
access to medicines, James Love (Director, Knowledge Ecology International)
delivered the following intervention.
*Human Rights Council Social Forum 2015*
Thank you for the invitation to speak today. I will get right to my main
point. All arguments about access and fairness are pitted against counter
arguments that strong intellectual property rights and high prices are
necessary for innovation, and that expanded access and greater fairness is
a short term benefit that comes at the expense of longer run benefits from
It is important to recognize the nature of this conflict, and to appreciate
and acknowledge that in our current way of thinking about funding R&D, such
conflicts do exist, even though they are often exaggerated, such as when
countries break patent monopolies for drugs for which there is almost no
access but also no revenues, prior to breaking the monopoly.
In our opinion, efforts to regulate drug company monopolies are failing.
They are failing to curb abuses of monopolies, and they are weak partly
because of the political power that these monopolies create.
Today the United States House of Representatives is collecting comments on
new legislative proposals to extend monopolies beyond everything that has
been proposed in the past, and next Tuesday, the United States Trade
Representative will hold a hearing to decide which developing countries
face new demands to expand monopolies and raise drug prices.
Extensive progress has been made in expanding access to treatments for HIV
in developing countries, but this is exceptional. For cancer and other
illnesses, things are much worse today than in the past, and not only in
On a personal note, my wife is a stage 4 cancer patient, alive today
because she has had access to cancer drugs that most women in the world
cannot afford. The most recent drug, TDM1, is $3,000 per week, too
expensive even for reimbursement agencies in the UK. It is a good drug, and
for some lucky patients, an amazing drug. It should be available to all
breast cancer patients that need it, not only those who can pay $3,000 per
We favor deep, radical, and transformative reforms, and every day more
people are coming to understand that such deep reforms are necessary to
access and fairness to be achieved, and to be sustainable.
These reforms concern the delinkage of R&D costs from product prices, and
the elimination of product monopolies, in favor of other financing
mechanisms, including some combination of research grants and contracts and
other subsidies, and delinked financial incentives, including robust
funding of large innovation inducement prize funds, such as those that have
been proposed for HIV/AIDS, cancer, and other areas.
In 28 June 2009, the Human Rights Council published a paper I wrote, on the
right to development.
*Paper on right to development: The Global Fund to Fight AIDS, Tuberculosis
and Malaria, the Special Programme for Research and Training in Tropical
Diseases and the right to development (28 June 2009)
In that paper, I was asked to propose criteria that would make the right to
development more concrete, and actionable. If I could summarize the main
points in that paper, I would say that institutions, including governments,
the WHO, etc, should consider if current funding levels and current
business models are consistent with success in achieving their own stated
objectives, in terms of human rights. If they are not, they have an
obligation to explore and eventually move towards new mechanisms and new
business models that are consistent with human rights.
It is our opinion that efforts to prop up and defend the current model for
funding medical R&D, despite massive evidence of failures in regards to the
right to health, is in itself a failure, and one that needs to be corrected.
More information about the Ip-health